NVCR
Novocure Ltd Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$13.15Close
$1.5BMarket cap
$10.03 – $19.9952-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 28 · weaker than 72% of stocks over 12 months
- Far from its high 34% below its 52-week high
- Distribution down-day volume 1.8× up-day volume over 50 sessions
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
34%
1wk
down 10.4%
price change
1mo
down 17.6%
price change
12-month return
up 3%
market up 11% ·
its own down 13%
F-score
4 / 9
Weak
Altman Z
0.48
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.3×
price / book
Earnings yield
down 9.7%
EBIT / enterprise value
Cheaper than
20%
of the market · expensive
Revenue growth
up 8%
year on year
EPS growth
—
latest quarter
Sales growth
up 16%
latest quarter · +0 pts
ROE
down 39%
return on equity
Free cash margin
down 12%
-$75.7M FCF
D/E
0.57
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- issued more shares
- gross margin narrowed
- profitability improving
- profits backed by cash
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
6.2%
$0.81 a day · 2×ATR $11.53
RS
28 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
0.55
50 sessions
Implied move
—
no scheduled report
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 3.7% over the year, from 109m to 112m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 77.3% to 74.5%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 29, 2026
Last shock
Jul 24, 2026-12% in one session2.1× volumeon results-25% since
Financials
- Gross 75%
- Net -21%
- Free cash -12%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Gross margin | 78% | 79% | 79% | 75% | 77% | 75% |
| Operating income | $30.4M | -$44.3M | -$89.5M | -$232.9M | -$170.5M | -$153.8M |
| Net income | $19.8M | -$58.0M | -$93.0M | -$207.0M | -$169.0M | -$136.2M |
| Net margin | 4% | -11% | -17% | -41% | -28% | -21% |
| Earnings per share | $0.18 | -$0.56 | -$0.89 | -$1.95 | -$1.57 | -$1.22 |
| Free cash flow | $84.2M | $58.6M | $9.4M | -$100.4M | -$69.2M | -$75.7M |
| Free cash margin | 17% | 11% | 2% | -20% | -11% | -12% |
| Cash | $234.7M | $208.8M | $115.3M | $240.8M | $163.8M | $93.5M |
| Long-term debt | $429.9M | $562.2M | $565.5M | $568.8M | $97.3M | $195.0M |
| Shareholders' equity | $476.5M | $410.5M | $441.2M | $362.5M | $360.2M | $340.5M |
| Shares outstanding | 102.33m | 103.97m | 105.05m | 107.08m | 108.52m | 112.49m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 23, 2026 | Quarterly ↗ | Jun 30, 2026 | 23d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Jul 24, 2025 | Quarterly ↗ | Jun 30, 2025 | 24d |
| Apr 24, 2025 | Quarterly ↗ | Mar 31, 2025 | 24d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Jul 25, 2024 | Quarterly ↗ | Jun 30, 2024 | 25d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Oct 1, 2026 | Regulation FD ↗ |
| Sep 9, 2026 | Director or officer change ↗ |
| Sep 1, 2026 | Other events ↗ |
| Jul 23, 2026 | Results ↗ |
| Jun 30, 2026 | Regulation FD ↗ |
| Jun 18, 2026 | Regulation FD ↗ |
| Jun 5, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 30, 2026 | Results ↗ |
| Apr 9, 2026 | Director or officer change ↗ |
| Mar 26, 2026 | Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |